Status:
COMPLETED
Antipsychotic Medication Extended Dosing Study
Lead Sponsor:
Centre for Addiction and Mental Health
Collaborating Sponsors:
National Alliance for Research on Schizophrenia and Depression
Conditions:
Schizophrenia
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
In patients stabilized on their antipsychotic and demonstrating evidence of good clinical response, there will not be a significant change in symptoms if their medication is decreased to every 2 days ...
Detailed Description
The present study is a 6-month, double-blind study of patients with schizophrenia stabilized on their current antipsychotic (monotherapy) for a period of at least 3 months. After providing informed co...
Eligibility Criteria
Inclusion
- DSM-IV diagnosis of schizophrenia or schizo-affective disorder
- Capacity to provide written, informed consent
- Stabilized\* on a single oral antipsychotic for at least three months (excluding CLOZAPINE or QUETIAPINE)
- Evidence of compliance with previous antipsychotic treatment, i.e. greater than 90% \* defined as 2 consecutively identical CGI evaluations (screening and baseline, at least one week apart)
Exclusion
- exposure to depot antipsychotic during 12 months prior to enrollment
- substance-related disorders according to DSM-IV
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00431574
Start Date
August 1 2002
End Date
October 1 2007
Last Update
February 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M5T 1R8